GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: AZD-3582 | AZD3582 | HCT-3012 | NO-naproxen
Compound class:
Synthetic organic
Comment: Naproxcinod is a NO-donating naproxen analogue prodrug. It is the first in a new class of anti-inflammatory and analgesic drugs known as cyclooxygenase-inhibiting nitric oxide donors (CINODs) [2], that are designed to lessen the gastrointestinal (and cardiovascular) side-effects of traditional NSAIDs. The NO released by the prodrug mediates this beneficial effect.
|
|
|||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| Anti-inflammatory and analgesic effects are associated with the naproxen released by this prodrug. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Osteoarthritis |
Disease Ontology:
DOID:8398 |
Naproxcinod has completed Phase 3 clinical trial for OA. | 5 |
| Duchenne muscular dystrophy |
Disease Ontology:
DOID:11723 OMIM: 19518854 |
Naproxcinod has orphan drug designation for DMD in Europe and the US. | |